Clinical Trial Update: A Study for Treatment of Superficial Bladder Cancer Using OGX-427 [Phase 1]

View source ↗

Summary

This clinical trial update covers a Phase 1 study of OGX-427 (apatorsen) for superficial bladder cancer, sponsored by Vancouver Coastal Health.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• OGX-427 (apatorsen)

Snippet

Sponsor: Vancouver Coastal Health | Conditions: Bladder Cancer | Phase 1 | Status: UNKNOWN